Global In-Vitro Colorectal Cancer Screening Tests Market

In-Vitro Colorectal Cancer Screening Tests Market Size, Share, Growth Analysis, By Product Type(Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests, Guaiac FOB Stool Test), By End User(Hospitals, Clinics, Diagnostics laboratories, Ambulatory Surgical Centers), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35E2011 | Region: Global | Published Date: July, 2036
Pages: 200 | Tables: 72 | Figures: 75

In-Vitro Colorectal Cancer Screening Tests Market Insights

In-Vitro Colorectal Cancer Screening Tests Market size was valued at USD 22.68 billion in 2019 and is poised to grow from USD 23.79 billion in 2023 to USD 64.7 billion by 2031, growing at a CAGR of 11.1% in the forecast period (2024-2031).

Adenomas, polyps, and colorectal cancer symptoms can all be found with in-vitro tests for colorectal cancer screening. A disorder known as colorectal cancer is characterised by the abnormal proliferation of cells in the colon, rectum, and large intestine. Some of the frequently used screening tests include the guaiac FOB stool test, lateral flow immuno, transferrin assays, methylated gene, biomarker, and faecal occult blood (FOB) test. In-vitro colorectal cancer screening procedures employ cameras that take pictures of the digestive system and send them to a recorder fastened to the patient's waist. They are seldom intrusive and can help with early cancer detection. In-vitro colorectal cancer screening procedures are therefore frequently carried out in clinics, hospitals, and diagnostics laboratories. The main factors anticipated to propel the in-vitro colorectal cancer screening tests market over the projected period are the rising occurrences of colon and rectal cancer and the release of innovative screening tests utilising genetic testing. The market for in-vitro colorectal cancer screening tests is anticipated to grow as a result of the introduction of government regulations aimed at requiring the use of cancer screening tests, rising demand for novel, minimally invasive tests that screen for colorectal cancer using DNA and genetic biomarkers, and the rising prevalence of colorectal cancer.

US In-Vitro Colorectal Cancer Screening Tests Market  is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

In-Vitro Colorectal Cancer Screening Tests Market size was valued at USD 22.68 billion in 2019 and is poised to grow from USD 23.79 billion in 2023 to USD 64.7 billion by 2031, growing at a CAGR of 11.1% in the forecast period (2024-2031).

The existence of several international players defines the global market. To increase their market share, businesses use a variety of techniques, including partnerships, agreements, regional growth, mergers, acquisitions, and new product creation. In our in-vitro colorectal cancer screening tests market reports, some of the leading quality in-vitro colorectal cancer screening tests manufacturers are as follows: Abbott (US), F. Hoffmann-La Roche AG (Switzerland), Quest Diagnostics (US), Sysmex Corporation (Japan), Siemens Healthcare (Germany), Alere Inc. (US), Eiken Chemical (Japan), Siemens AG (Germany), OncoCyte Corporation-Biotime (US), Merck KGaA (Germany). 'Abbott Laboratories', 'Beckman Coulter, Inc.', 'Bio-Rad Laboratories, Inc.', 'Exact Sciences Corporation', 'F. Hoffmann-La Roche AG', 'Genomic Health, Inc.', 'Hologic, Inc.', 'Illumina, Inc.', 'Invitae Corporation', 'Laboratory Corporation of America Holdings', 'Myriad Genetics, Inc.', 'Natera, Inc.', 'NeoGenomics Laboratories, Inc.', 'QIAGEN N.V.', 'Quest Diagnostics Incorporated', 'Siemens Healthineers AG', 'Sysmex Corporation', 'Thermo Fisher Scientific Inc.', 'VolitionRX Limited', 'Zymo Research Corporation'

The prevalence of colorectal cancer (CRC) is increasing as a result of numerous causes, including the ageing population, the adoption of an unhealthy lifestyle, and diabetes.

One of the main factors propelling the market's expansion is the rising frequency of colorectal cancer among the general population. Additionally, growing public awareness of the advantages of early cancer detection and prompt treatment is favourably affecting market expansion. The market is expanding as a result of numerous technological developments, such as the inclusion of genetic testing in cancer screening tests. These tests support early detection, the creation of treatment regimens, stopping the spread of cancerous cells, and lowering the dangers of afflicted conditions.

The North American, European, Asian-Pacific, Latin American, and Middle Eastern regions of the market for in-vitro colorectal cancer screening tests were used to split the market for regional analysis. In-vitro testing for colorectal cancer were the market leader in 2021 in North America.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global In-Vitro Colorectal Cancer Screening Tests Market

Report ID: SQMIG35E2011

$5,300
BUY NOW GET FREE SAMPLE